ADM:LSEAdmiral Group plc Analysis
Data as of 2026-03-14 - not real-time
£3,280.00
Latest Price
4/10Risk
Risk Level: Medium
Executive Summary
Admiral Group is trading at a price well below its discounted cash‑flow estimate, suggesting a material upside potential. The stock’s price‑to‑earnings multiple sits under the industry average, while the dividend yield of nearly five percent offers attractive income. Technical signals are mixed: the 14‑day RSI is in overbought territory, yet the MACD histogram remains firmly bullish, and volume is trending higher, indicating continued buying interest. Support sits around 2,806 pence, with resistance near 3,302 pence, and the current price of 3,280 pence is just shy of that ceiling. Recent UBS research upgraded the stock to “buy” and lifted its 12‑month target, adding momentum to the upside case. The company’s ROE exceeds 50 percent and free cash flow comfortably covers the 73 percent payout ratio, underscoring dividend sustainability.
Low beta and a modest volatility profile reduce market‑related risk, while the insurance sector’s regulatory environment remains stable. Geographic exposure is concentrated in the UK, presenting moderate regional risk, but the firm’s diversified product suite mitigates concentration concerns. Overall, the combination of undervaluation, strong cash generation, and a supportive dividend makes Admiral Group a compelling candidate for investors seeking value with income.
Low beta and a modest volatility profile reduce market‑related risk, while the insurance sector’s regulatory environment remains stable. Geographic exposure is concentrated in the UK, presenting moderate regional risk, but the firm’s diversified product suite mitigates concentration concerns. Overall, the combination of undervaluation, strong cash generation, and a supportive dividend makes Admiral Group a compelling candidate for investors seeking value with income.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 7/10
Key Factors
- RSI indicates short‑term overbought conditions
- Bullish MACD supports continued upside
- UBS upgrade adds near‑term confidence
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Price below DCF fair value suggests upside
- High ROE and strong free cash flow
- Sustainable dividend with solid payout coverage
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Stable, low‑beta business model
- Consistent dividend yield around 5%
- Resilient insurance franchise with diversified geography
Key Metrics & Analysis
Financial Health
Revenue Growth-4.10%
Profit Margin14.79%
P/E Ratio13.5
ROE52.96%
ROA7.66%
Debt/Equity131.16
P/B Ratio673.8
Op. Cash Flow£436.5M
Free Cash Flow£1.1B
Industry P/E16.4
Technical Analysis
TrendNeutral
RSI75.0
Support£2,806.00
Resistance£3,302.00
MA 20£2,974.40
MA 50£2,916.16
MA 200£3,206.11
MACDBullish
VolumeIncreasing
Fear & Greed Index72.88
Valuation
Fair Value£4,951.77
Target Price£3,276.73
Upside/Downside-0.10%
GradeUndervalued
TypeValue
Dividend Yield4.93%
Risk Assessment
Beta0.02
Volatility31.14%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.